全文获取类型
收费全文 | 3823篇 |
免费 | 412篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 43篇 |
儿科学 | 236篇 |
妇产科学 | 34篇 |
基础医学 | 539篇 |
口腔科学 | 122篇 |
临床医学 | 442篇 |
内科学 | 764篇 |
皮肤病学 | 42篇 |
神经病学 | 218篇 |
特种医学 | 189篇 |
外科学 | 420篇 |
综合类 | 80篇 |
一般理论 | 2篇 |
预防医学 | 514篇 |
眼科学 | 45篇 |
药学 | 352篇 |
中国医学 | 2篇 |
肿瘤学 | 205篇 |
出版年
2022年 | 30篇 |
2021年 | 56篇 |
2019年 | 56篇 |
2018年 | 69篇 |
2017年 | 53篇 |
2016年 | 52篇 |
2015年 | 68篇 |
2014年 | 100篇 |
2013年 | 136篇 |
2012年 | 149篇 |
2011年 | 154篇 |
2010年 | 136篇 |
2009年 | 103篇 |
2008年 | 146篇 |
2007年 | 173篇 |
2006年 | 156篇 |
2005年 | 129篇 |
2004年 | 141篇 |
2003年 | 129篇 |
2002年 | 130篇 |
2001年 | 107篇 |
2000年 | 117篇 |
1999年 | 135篇 |
1998年 | 93篇 |
1997年 | 68篇 |
1996年 | 72篇 |
1995年 | 66篇 |
1994年 | 72篇 |
1993年 | 49篇 |
1992年 | 98篇 |
1991年 | 104篇 |
1990年 | 101篇 |
1989年 | 78篇 |
1988年 | 86篇 |
1987年 | 77篇 |
1986年 | 65篇 |
1985年 | 61篇 |
1984年 | 42篇 |
1983年 | 46篇 |
1982年 | 38篇 |
1981年 | 30篇 |
1979年 | 36篇 |
1978年 | 29篇 |
1977年 | 36篇 |
1976年 | 36篇 |
1975年 | 26篇 |
1974年 | 37篇 |
1973年 | 37篇 |
1972年 | 30篇 |
1970年 | 27篇 |
排序方式: 共有4249条查询结果,搜索用时 15 毫秒
101.
The development and initial validation of a questionnaire to measure help‐seeking behaviour in patients with new onset rheumatoid arthritis 下载免费PDF全文
Rebecca J. Stack BSc MBPsS MSc PhD Christian D. Mallen BMBS FRCGP PhD Chris Deighton BMedSci MD FRCP Patrick Kiely BSc MBBS PhD FRCP Karen L. Shaw BSc MBPsS PgCert PhD Alison Booth RN MSc Kanta Kumar RN MSc Susan Thomas BA MA Ian Rowan Rob Horne BSc MSc PhD MRPharm Peter Nightingale BSc PhD Sandy Herron‐Marx RGN DPSN BA PGcap PhD Clare Jinks BA MPhil PhD Karim Raza FRCP PhD 《Health expectations》2015,18(6):2340-2355
102.
Douglass A Morrison Gulshan Sethi Jerome Sacks William Henderson Frederick Grover Steven Sedlis Rick Esposito Kodagundi B Ramanathan Darryl Weiman J David Talley Jorge Saucedo Tamim Antakli Venki Paramesh Stuart Pett Sarah Vernon Vladimir Birjiniuk Frederick Welt Mitchell Krucoff Walter Wolfe John C Lucke Sundeep Mediratta David Booth Charles Barbiere Dan Lewis 《Journal of the American College of Cardiology》2002,39(2):266-273
OBJECTIVES: This study was designed to compare the three-year survival after percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) in physician-directed and patient-choice registries with the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME) randomized trial results. BACKGROUND: The AWESOME multicenter randomized trial and registry compared the long-term survival after PCI and CABG for the treatment of patients with medically refractory myocardial ischemia and at least one additional risk factor for adverse outcome with CABG. The randomized trial demonstrated comparable three-year survival. METHODS: Over a five-year period (1995 to 2000), 2,431 patients with medically refractory myocardial ischemia and at least one of five risk factors (prior heart surgery, myocardial infarction within seven days, left ventricular ejection fraction <0.35, age >70 years, intra-aortic balloon required to stabilize) were identified. By physician consensus, 1,650 patients formed a physician-directed registry assigned to CABG (692), PCI (651) or further medical therapy (307), and 781 were angiographically eligible for random allocation; 454 of these patients constitute the randomized trial, and the remaining 327 constitute a patient choice registry. Survival for CABG and PCI was compared using Kaplan-Meier curves and log-rank tests. RESULTS: The CABG and PCI 36-month survival rates for randomized patients were 79% and 80%, respectively. The CABG and PCI 36-month survival rates were both 76% for the physician-directed subgroup; comparable survival rates for the patient-choice subgroup were 80% and 89%, respectively. None of the global log-rank tests for survival demonstrated significant differences. CONCLUSIONS: Both registries support the randomized trial conclusion: PCI is an alternative to CABG for some medically refractory high-risk patients. 相似文献
103.
D. W. Oliver M. W. C. Booth V. F. M. Kernick T. T. Irvin W. B. Campbell 《International journal of colorectal disease》1998,13(5-6):228-231
Anal dilatation is used as a simple method of treatment and has been used for both anal fissure and haemorrhoids. This study
examined longer-term results among a cohort of 162 patients, 132 of whom responded to a detailed questionnaire, an 82% response
(66 patients were male; age range 17–75 years, median 42 years). Follow-up ranged from 16 months to 36 months (median 27 months)
after anal dilatation (68 patients for fissure, 32 for haemorrhoids, and 32 for both). In the early months after dilatation,
83% had symptomatic improvement and 76% remained improved. Five (7%) patients with fissure and 11 with haemorrhoids (17%)
required further hospital treatment, while 10% and 17%, respectively, had received further treatment from their general practitioners
(GPs). Seventy-one percent said they would have a further anal dilation if symptoms recurred. There was no difference in results
obtained by surgeons of different seniority. Complications – bleeding (29%) and difficulty controlling flatus (15%) or faeces
(8%) – resolved in all cases. The results of anal dilatation for fissure are generally satisfactory in the longer term, with
a trend toward better symptom relief in patients with fissure compared with those with haemorrhoids. We do not recommend anal
dilatation as the sole treatment of patients with haemorrhoids, but it may be a useful adjunct to other treatments such as
banding or sclerotherapy. Morbidity was generally acceptable and the majority of our patients would be prepared to have this
procedure again if their symptoms were to return.
Accepted: 14 September 1998 相似文献
104.
105.
106.
Burns Heather Collins Abigail Marsden Paul Flood Terence J. Slatter Mary A. Booth Claire Xu-Bayford Jinhua Leahy Timothy Ronan 《Journal of clinical immunology》2021,41(8):1950-1953
Journal of Clinical Immunology - 相似文献
107.
108.
109.
110.
The interaction of the multimeric glycoprotein von Willebrand Factor (vWF) with its platelet membrane receptor, the glycoprotein (GP) Ib-IX complex plays a key role in the initial adhesion of platelets to the vascular subendothelium at high shear blood flow. The GP Ib-IX-binding site is only expressed following activation of vWF, a process that regulates vWF-mediated platelet adhesion. Binding of vWF to the GP Ib-IX complex involves the vWF A1 internal repeat domain, which also contains distinct binding sites for sulfatides, heparin, and the non-physiological modulators of the vWF-GP Ib-IX interaction, ristocetin and botrocetin. With the ultimate aim of further defining the mechanism of vWF modulation, we have analyzed the ability of various polyanionic compounds, including aurintricarboxylic acid, Evans blue, fucoidan, and a range of sulfated and phosphorylated sugars, to inhibit specific binding of purified vWF to immobilized sulfatides and heparin, and the ristocetin- and botrocetindependent binding of vWF to the platelet GP Ib-IX complex. Firstly, it was confirmed using a solid-phase binding assay that, like sulfatides, heparin specifically bound to a purified 39/WkiloDalton fragment of vWF (Leu-480 to Gly-718) that encompasses the A1 domain. Secondly, the ability of a number of polyanionic compounds to inhibit binding of vWF to heparin, but not to immobilized sulfatides, supported previous data suggesting that heparin and sulfatides bind to distinct sites on vWF. In addition, aurintricarboxylic acid, Evans blue and fucoidan all inhibited binding of vWF to both heparin and sulfatides with similar ICso values. Thirdly, many of the compounds tested that inhibited binding of vWF to heparin also effectively inhibited both ristocetin- and botrocetin-dependent binding of vWF to the GP Ib-IX complex on platelets, whereas none of the compounds tested blocked vWF binding to sulfatides and GP Ib-IX but not heparin. The majority of compounds tested inhibited the vWF-platelet interaction to a comparable degree in the presence of ristocetin or botrocetin, suggesting a similar mechanism for inhibition irrespective of the modulator used. These combined experiments provide evidence for an electrostatic model of vWF modulation, and suggest that the heparin-binding domain of vWF may be an important regulatory site involved in the adhesion of vWF to the platelet GP Ib-IX complex. 相似文献